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http:WHAT THIS PAPER ADDS
Paradoxically, the advent of several national screening programs for AAA coincides with multiple reports indi-
cating a changing epidemiology of the AAA disease: mainly, a decrease in prevalence and mortality from
ruptured AAA during the recent decade is evident, with possible implications for the validity of screening for
AAA. This review summarizes the most recent data concerning screening for AAA that could affect its justiﬁ-
cation, and highlights areas with lack of information.Objectives: Serving as the basis for implementation of several national AAA screening programmes, four large
randomised controlled trials provided evidence of a reduction in AAA mortality by ultrasound-based screening
among elderly men. Recently, reports of falling AAA prevalence and mortality unrelated to AAA screening have
emerged, coinciding with major additional epidemiological changes in the population, as well as improvements in
AAA repair. These recent changes may individually, and in concert, affect the rationality of AAA screening. The aim
of this paper was to present an up-to-date review of AAA-screening within the context of a rapidly changing AAA
epidemiology.
Methods: Topical review of the literature focusing mainly on randomised controlled trials, meta-analyses, and
contemporary observational AAA-screening studies.
Conclusions: Summarising RCT results and recent studies; contemporary one-time screening of men for AAA
appears highly cost-effective, and seems to remain an effective preventive health-measure. However, several
issues regarding screening need to be addressed: most importantly; the current degree of incidental detection
of AAAs, the threshold diameter for follow-up, targeted screening in risk groups, and the possible need for re-
screening in an elderly population with ever increasing longevity.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Four large randomized controlled trials (RCTs),1e4 random-
izing male populations between 1988 and 1999, with AAA
prevalence rates of 4e7.2%, to ultrasound based screening
or no screening for AAA demonstrated a 40% reduction in
AAA speciﬁc death.5 The Multicentre Aneurysm Screening
Study (MASS),6 the largest RCT, subsequently demonstrated
a 3% reduction in all cause mortality after 13 years’ follow
up. These results were the basis for initiating national
screening programs in Sweden, the UK, and the USA.7,8of original article: http://dx.doi.org/10.1016/j.ejvs.2014.09.007
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//dx.doi.org/10.1016/j.ejvs.2014.08.029Since the time of randomization in these inﬂuential
studies, reports of a changing epidemiology9e12 of AAA
disease have been published, and screening detected
prevalence rates of 1.1e1.7% have been reported.9,13,14
Concurrently, major improvements in surgical manage-
ment of AAA have been established. AAA repair with
improved short- and long-term outcomes12,15,16 is offered
to healthier17 and increasingly long lived populations.18
The aim of this topical review is to summarize the up to
date evidence concerning AAA screening, identify areas
lacking information, and to suggest possible directions for
future research.
AAA screening evidence base
AAA is a disease exceptionally well suited to screening, and
ultrasound based screening for AAA meets all criteria for a
screening program according to the WHO.19 After the ﬁrst
population based AAA screening study by Collin et al.,20 in
Table 1. Overview of the randomized population based screening trials.
Characteristic Chichester, UK Viborg, Denmark MASS, UK Western Australia
Number randomized 15,775 12,628 67,800 41,000
Gender Men and women Men Men Men
Age (years) 65e80 65e73 65e74 65e79
Recruitment 1988e1990 1994e1998 1997e1999 1996e1998
AAA repair at 6 cm 5 cm 5.5 cm e
Attendance 68% 76% 80% 70%
Prevalence of AAA 4% (7.6% in men) 4% 4.9% 7.2%
Last follow-up 15 years 14 years 13 years 11 years
Last published follow-up 2007 2010 2012 2008
Hazard ratio AAA mortality, last follow-up 0.89 (0.60e1.32) 0.34 (0.20e0.57) 0.58 (0.49e0.69) e
Hazard ratio all-cause mortality, last follow-up 1.0 (0.90e1.12) 0.98 (0.93e1.03) 0.97 (0.95e0.99) 0.99 (0.94e1.04)
Degree of incidental detection at last follow-upc 35.5%a 46.0% 42.0%b e
AAA ¼ abdominal aortic aneurysm.
a Study at this follow up lacks differentiation between emergency surgery for ruptured and intact AAA.
b Rate of repair for symptomatic intact AAAs not stratiﬁed for attenders vs. non-attenders in invited group. Symptomatic repairs thus
excluded from calculation.
c Incidental detection and repair rate. Ratio of intact AAA repair in control group vs. invited screened group, [RateControl/RateScreened].
Estimated from tabulated data in publications.
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trials1e4 were launched and delivered their long-term re-
sults (Table 1). The trials, conducted in the UK, Denmark,
and Western Australia, recruited subjects during 1988e
1999, and follow up data are available up to 15 years.6,21e23
A Cochrane meta-analysis of the four RCTs in 2007
concluded that an invitation to screening for elderly men
reduced AAA speciﬁc mortality by 40% after approximately
3e5 years of follow up.5 A meta-analysis of all cause mor-
tality including all four RCTs found a 2.7% reduction in all
cause mortality after 11e15 years of follow up.24
In the Multicentre Aneurysm Screening Study (MASS),
after 13 years, 46 deaths from AAA were prevented by
inviting 10,000 men to screening, which implied that 217
men would have to be invited to prevent one death from
AAA. Invitation to screening reduced the risk of AAA death
by 42% and 52% for those actually attending screening. The
number of elective AAA repairs conducted in the invited
group was twice that of the control group, and the number
of emergency repairs was halved.
In Gloucestershire, UK, AAA screening has been offered
to 65 year old men since 1990, and after 20 years the
number of repairs for ruptured AAA has steadily decreased,
indicating a beneﬁcial effect of AAA screening. However,
over the same time period the AAA prevalence in 65 year
old men fell from 4.8% to 1.1%.13 Thus, an important
contributing cause of decreased AAA emergency surgery
may also be an overall decrease of disease occurrence.
A screening trial in Huntingdon 1991e2003, using a
stepped wedge design, demonstrated a 45% AAA mortality
reduction, and it was estimated that each prevented death
from AAA extended the lifespan by 6.9 years.25Abdominal ultrasound and diagnosis
All four screening RCTs employed a maximum infrarenal
aortic diameter of 30 mm or more, measured by ultrasound,
as the diagnostic criterion for an AAA. There is, however, noclear consensus on how to measure the maximum aortic
diameter.26 In MASS inner to inner (ITI) wall measurement
was used,27 and consequently it is used in the current UK
National Health Service AAA screening programme
(NAAASP); in Gloucestershire the outer margin of the
anterior wall to the inner margin of the posterior wall
(leading edge to leading edge [LELE]) was measured,28 also
adopted in the national Swedish AAA screening pro-
gramme8; in Huntingdon the outer to outer walls (OTO) was
measured, previously used in the UK small Aneurysm Trial
and adopted in the current UK intervention criteria.29
A recent study evaluated the various methods of mea-
surement, and concluded that all methods have high vari-
ability and that differences between the methods may
impact clinical decision making.30 Further analysis of data
from that study suggested that the estimated AAA preva-
lence could vary from 22% (ITI) to þ36% (OTO),
depending on the method chosen.Changing epidemiology and surgical management
Until the late 1990s and early 2000s, prevalence rates of 4e
9% among elderly men were reported.1,4,31e33 Indications of
rising prevalence rates were also reported at this time,34,35
as well as increasing rupture rates and mortality up until
the early 2000s.11,36,37 During the past decade, however,
multiple studies report prevalence rates below 2% in 65-
year-old men.9,13,14 Similar ﬁndings of low AAA prevalence
(2.3%) were also evident when screening 70-year-old men in
Sweden.38 Falling rates of rupture and AAA mortality unre-
lated to AAA screening were also reported.10,11
The dominating and modiﬁable risk factor for AAA is
smoking.9,32,39,40 It has been estimated that smoking causes
75% of all AAA cases in the population.9,32 In many western
countries the smoking rate has fallen signiﬁcantly over the
last decades.9,11,37 Reduced smoking rates seem to markedly
coincide with falling rates of AAA prevalence in Sweden
(Fig. 1) a pattern that is evident for AAA mortality as
Figure 1. Historical and contemporary AAA prevalence rates pre-
sented with time trends in smoking. The prevalence of AAA in 65
year old men and 70 year old women in Sweden as determined at
1980 and 2010 (right y-axis),9,35,66 plotted together with rates of
daily smokers in Sweden over the same time period (left y-axis).
Source: Statistics Sweden.83
Update on Screening for Abdominal Aortic Aneurysm 661well.11,37,41 Falling AAA mortality is, however, not global,41
and exceptions to this falling trend are evident in countries
not reporting falling smoking rates, such as Denmark42 and
Austria.
During the last two decades surgical management of AAA
has changed considerably, with an increased use of endo-
vascular repair (EVAR), especially among elderly people, and
an increased rate of elective AAA repair.11,15,43 Using the
IMPACTmodel, Anjum et al.11 demonstrated that, second to
falling smoking rates, the increased rate of elective AAA
repairs may also signiﬁcantly have contributed to the recent
reduction in AAA mortality. Short-44,45 and long-term out-
comes16 have improved signiﬁcantly after AAA repair.
Ongoing screening initiatives
Between 2009 and 2013, NAAASP rolled out in England, and
is now the largest national population based screening
program, inviting 300,000 65 year old men annually.46
Scotland, Wales, and Northern Ireland are implementing
screening programs.7 Since 2007, when the Screening
Abdominal Aortic Aneurysms Very Efﬁciently (SAAAVE) act
was implemented in the USA, making 65 year old men
newly enrolled in Medicare eligible for a free abdominal
aortic ultrasound, there has been only a modest increase in
abdominal aortic ultrasounds.47 Approximately 10% un-
dergo the reimbursed ultrasound, and no effects on AAA
repair rates have been observed. Sweden has achieved
>99% national coverage of population based AAA screening
between 2006 and 2013, targeting 65 year old men, and 5
year follow up data are available.48 Denmark is conducting a
randomized AAA screening trial in a population of 50,000
men, recruited between 2008 and 2010.49 In Oslo, Norway,
an observational AAA screening study is currently enrolling
male subjects (Clinicaltrials.gov).
Ethics, harm, and beneﬁts
Not all screening detected AAAs will need repair, and only
approximately half the repaired AAAs would have ruptured.This highlights the ethical dilemma that a small number of
men will die from undergoing elective repair for a screening
detected AAA that would never have ruptured. The risk of
death from elective repair is estimated to 1 in 10,000 men
invited to screening.50 The risk of death following repair also
exists in incidentally detected AAAs, and it is higher than for
screening detected AAAs, probably due to different timing
of surgery, higher rates of comorbidity, and less standard-
ized care.51e53
In the ﬁnal follow up in MASS,6 reduced all cause mor-
tality was shown in the screened group, possibly a result of
increased awareness and subsequent risk factor manage-
ment of previously undetected cardiovascular morbidity.
This effect on all cause mortality was, however, challenged
in the latest systematic evidence review of AAA screening
for the USPSTF.54 Also, the growing number of screening
detected small AAAs under surveillance presents an
appealing opportunity for medical treatment leading to a
reduction of AAA growth; however, to date no drug has
displayed a convincing effect on AAA growth, as reported in
a comprehensive meta-analysis of 18 international
studies.55 There is a multitude of ongoing studies address-
ing pharmacological modulation of AAA growth.
The issue of loss of quality of life (QoL), resulting from
making an unknown disease known to a patient, is associ-
ated with conﬂicting evidence. Several studies on the effect
of screening show a mild, transient reduction in QoL.1,6,56e58
A possible sustained impairment of QoL caused by screening
signiﬁcantly affects cost-effectiveness.59 Further research on
the effects of surveillance management and how to inform
patients is therefore indicated.
The small but clear risk of mortality following elective
repair of a screening detected AAA highlights the para-
mount importance of balanced information when inviting
people to screening. In a paper on screening ethics, it was
evident that although an evidence based mortality beneﬁt
was a natural prerequisite, the ethics of AAA screening must
fundamentally rest on the fact that a patient’s decision to
submit to prophylactic healthcare is completely free and
truly informed.60Effect and cost-effectiveness
With falling prevalence rates in many countries, the ratio-
nale of AAA screening has rightly been called into question.
Many model based, and in study based, cost-effectiveness
analyses (CEA) of AAA screening have been conducted
during the past decade (Table 2). It is worth noting that a
Danish systematic review61 pointed to quality issues in
some of the historical model studies, which should be
considered when judging the combined results of cost-
efﬁciency studies. Also, reliable modern data on observed
rupture risks are lacking, since natural history studies are
ethically impossible to perform. The studies used a variety
of age groups and prevalence rates. However, the lifetime
absolute risk reduction (ARR) from death from AAA calcu-
lated for each percent in AAA prevalence appears similar
between the studies, with a median rate of 7.8 per 10,000
Table 2. Cost-effectiveness analyses of AAA screening in men 2005e2014.
Strategy Method Prevalence (%) Follow-up Screening effect
QALYs gained
per 10,000 invited
LYs gained per
10,000 invited
ARR for AAA death
per 10,000 invited
ICER Euros/QALY
gained
ICER Euros/LY
gained
Crude Adjusteda Crude Adjusteda Crude Adjusteda
One time, 65-year-old men
Svensjö et al.50 Model 1.7 Lifetime (40 years) 109 64.1 142 83.5 16.4 9.6 7570 5783
13 years 57 33.5 72 42.4 15.1 8.9 14,706 11,558
10 years 37 21.8 46 27.1 13.4 7.9 23,265 18,552
Søgaard et al.73 Model 3.3 Lifetime 1144 346.7 e e 25 7.6 685 e
Spronk et al.75 Model 11.5 Netherlands Lifetime 759b 66.0 970 84.3 85.9 7.5 e 4340
Norway Lifetime 449b 39.0 570 49.6 91.3 7.9 e 9860
Ehlers et al. 200976 Model 4.0 Lifetime Not given Not given 27 6.8 61,593
Montreuil et al.77 Model 4.2 Lifetime 190 45.2 53.5 12.7 5204
Kim et al.78 Model 5.0 Lifetime (30 years) 200 40.0 250 50.0 Not given e 4789 3741
Wanhainen et al.59 Model 5.5 Lifetime e e 200 36.4 23c 4.2 12,380 9328
Henriksson et al.79 Model 4.9d Lifetime 200 40.8 250 51.0 Not given e 11,092 8874
Giardina et al.80 Model 2.9 Lifetime 110 37.9 140 48.3 32.4e 11.2 5673 4415
Lindholt et al.22 In study 4.0 14 years 700 175.0 800 200.0 57.1 14.3 179 157
MASS, Thompson et al.81 In study 4.9 10 years e e 132 26.8 41.6 8.5 e 10,139
MASS, MASS-group82 In study 4.9 4 years e e 22 4.5 13.9 2.8 58,051 45,796
Median, of life-time analyses 43.0 50.0 7.8 6622 5783
Note. Model ¼ using Markov model or Monte Carlo analysis; In study ¼ in study CE evaluation/analysis; QALY ¼ quality adjusted life year; LY ¼ life-year; ARR ¼ absolute risk reduction;
ICER ¼ incremental cost-efﬁciency ratio; ICERs reported before 2010 were updated to 2012 values using GDP deﬂator indices, and non-euro currencies were converted using mean exchange
currency of 2012.
a Adjusted: calculated effect presented per 1% in AAA prevalence.
b QALYs gained per 10,000 estimated based on quality adjusted life-expectancy versus life years of life-expectancy in study.
c Based on reported ARR at 10 years in model, thus a higher value would be expected at lifetime analysis.
d Prevalence for 65yo men extrapolated to 65yo men from 65 to 75yo using random effects method, according to reported methods in publication.
e Based on reported numbers needed to screen to prevent one AAA-related death and adjusted for attendance rate of 61.6%.
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Figure 2. Two way sensitivity analysis of AAA screening cost-
effectiveness boundaries as a function of AAA prevalence and
degree of incidental detection of AAA in the population. Data is
based on a willingness to pay threshold of V25,000 per QALY
and follow-up 13 years after screening. Based on data from Svensjö
et al.50 Grey area indicates within which boundaries screening
is cost-effective with willingness to pay of V25,000 per QALY
gained. For reference, dotted vertical lines indicate range for
contemporary reported AAA prevalence among 65 year old men
(1.5e1.7%),9,46,84 and horizontal dotted lines indicate the docu-
mented range (35e46%)6,21,22 of incidental detection extracted
from three AAA screening RCTs with long-term follow up.
Update on Screening for Abdominal Aortic Aneurysm 663invited for the most recent analyses, available. Similarly, the
incremental cost-effectiveness ratio (ICER) in euros per
quality adjusted life year (QALY) gained and life year (LY)
gained display a median of V6622 and V5783, respectively;
however, with wide ranges (V685e61,593) and (V3741e
9860).
Applying the median ARR for each percent in prevalence
to contemporary prevalence rates in 65 year old men from
national population based screening programs from the UK
and Sweden, an ARR of 10e15 per 10,000 invited could be
expected. Speciﬁcally, at a prevalence of 1.7%, an ARR of
15.1 per 10,000 invited to screening after 13 years’ follow
up (the equivalent of the maximum available follow up
time in MASS) was estimated in the most recently pub-
lished cost-effectiveness analysis linked to the national
screening program in Sweden.50 In that study, AAA
screening of 65 year old men was cost-effective down to a
prevalence of 0.5%, and it was estimated that each pre-
vented death from rupture saved 8.7 life years. At the
various prevalence rates studied, all but one recent cost-
effectiveness analysis estimated a lifetime cost per QALY
gained with screening that was below the commonly
referenced cost efﬁciency threshold value of V25,000 from
the National Institute of Clinical Excellence (NICE) in the
UK62 (Table 2).
A Cochrane systematic review63 estimated the ARR for
death from breast cancer with mammography screening as
ﬁve per 10,000 invited after 10 years of follow up, although
much lower and higher ARR estimations have been re-
ported. The corresponding ARR for death from colorectal
cancer by fecal occult blood screening was estimated as 15
per 10,000 invited after 8e18 years of follow up in a
Cochrane analysis.64 A European Prostate Cancer Screening
study demonstrated an ARR of 7.1 per 10,000 invited after a
median of 9 years’ follow-up.65 Thus, at contemporary
prevalence rates of AAA, one time screening of 65 year old
men appears to be a comparably effective preventive health
measure.
The number of previously unknown AAAs detected at
the time of screening is a major determinant of the ARR
and cost-effectiveness of the screening system.50 An
increased proportion of incidentally detected AAAs, for
example by widespread CT scanning for the suspicion of
other diagnoses, would effectively reduce the number of
previously unknown AAAs detected at screening. This
would reduce the prevalence of screening detected AAAs
and subsequently reduce the cost-efﬁciency and clinical
effect of screening (Fig. 2). The observed increasing
longevity of elderly people, falling peri-operative mortality,
and more elderly being eligible for preventive surgery
could increase cost-efﬁciency of screening as well as life
years saved.
In summary, a majority of cost-effectiveness analyses
estimate AAA screening to be cost-effective, and this seems
to be maintained at present. The observed falling preva-
lence is counterbalanced by lower peri-operative mortality
and increased longevity, resulting in an unchanged low cost
per QALY gained.Areas lacking information
Women. Women consistently display lower prevalence
rates for AAA than men of the same age, with roughly one
fourth to one sixth of that of men.66 In the UK Small
Aneurysm Trial studying patients with AAA between 4.0 and
5.4 cm, women displayed a threefold increased rupture rate
compared with men with equal diameter of AAA.67 A cur-
rent review of AAA in women68 concluded that women
undergo EVAR less often, mostly due to unfavorable neck
anatomy, and seems to have a worse long-term outcome
than in men. Women were also less likely to undergo repair
if their AAA ruptured; mortality was higher after repair, and
ruptures occurred later in life.
The only randomized screening trial including women,
with a AAA prevalence of 1.3%, was the Chichester trial,2,69
showing no survival beneﬁt for women. The number of
women screened was only 3,052, however, and the study
may therefore have been underpowered to detect a mor-
tality beneﬁt in the female population. A cost-effectiveness
model analysis from 2006 demonstrated that screening
women could be cost-effective due to higher rupture risk,
and concluded that women should not be excluded from
further evaluation for screening.70
In 2005, on the basis of available evidence, the United
States Preventive Services Task Force (USPSTF) recom-
mended against routine screening in women.71 Contrary to
this, the Society for Vascular Surgery (SVS) in the USA rec-
ommended that women, 65 years or older, who have ever
smoked or have a family history of AAA should be screened
664 S. Svensjö et al.with ultrasound.72 Currently, there is no reported ongoing
community based AAA screening of women in the world.
In a contemporary population based screening study of
5140 women,66 an AAA prevalence of only 0.4% was found
among 70 year old women in Sweden. Smoking was
strongly linked to AAA, with 95% of AAAs occurring among
women who had ever smoked, comprising 44% of the
cohort invited. It was concluded that population based
screening in women could be ruled out. However, the AAA
prevalence among smoking women (2.1%) was similar to
that of all 65 year old men (1.7%), indicating this group as a
possible target for selective screening (Fig. 3).
Sub-aneurysmal aortas and development of AAAs after a
normal scan. A consequence of establishing screening
programs is increased detection of small AAAs in need of
surveillance. There is no consensus on the threshold
diameter for continued surveillance after an aortic ultra-
sound. In the UK, NAAASP enters men with aortic diameters
of 30 mm or more into surveillance, whereas in the USA and
most of Sweden aortic diameters of 25 mm or more are
offered surveillance.7 The value of re-screening was
approached in a recent model study,73 which indicated only
a limited effect on saved lives at a signiﬁcantly increased
cost. Extensive surveillance data from established national
screening programs is, however, just now becoming avail-
able, and will provide a stronger foundation for cost-
efﬁciency modeling of re-screening strategies in the
future. In this setting, the natural history of sub-aneurysmal
aortas (25e29 mm) is of increasing interest. In the ﬁnal
follow up of MASS the long-term protective effect of
screening appeared to fall due to ruptures after 8 years
among men initially screened normal (<30 mm).6 Approx-
imately half of these ruptures occurred among those with a
sub-aneurysmal aorta (25e29 mm) at the time of screening.
Similar ﬁgures were derived from a large multicenter
observational study on 1696 subjects with sub-aneurysmal
aortas, where 60% had developed AAAs after 5 years.74 In
a Swedish longitudinal cohort study, where 3268 menFigure 3. Contemporary prevalence of screening detected AAA
among 65 year old Swedish men9 and 70 year old Swedish
women,66 stratiﬁed by smoking status. Error bars indicate 95%
conﬁdence intervals.invited to screening at age 65 were re-invited and re-
screened at age 70, 52.5% with sub-aneurysmal aortas
had progressed to an AAA after 5 years.48 Regarding the
clinical value of continued surveillance of these mostly small
aneurysms now present in 70-year-old men, it should be
remembered that this age was equivalent to the mean age
at inclusion in the MASS study.1 Although no clear evidence
exists regarding the clinical relevance of surveillance of
persons with a sub-aneurysmal aorta, valuable data are
accumulating from multiple ongoing screening programs.
With over 50% progressing to a true AAA within 5 years, it
would seem non-controversial to include this fairly small
cohort (<2%) of men in post-screening surveillance
programs.CONCLUSION
Presently, there is a large body of evidence indicating that
one time screening of 65 year old men is clinically relevant
and cost-effective. Despite a falling prevalence, contempo-
rary AAA screening in men still appears cost-effective,
possibly by counterbalancing the low prevalence with
improved surgical methods and improved long-term sur-
vival. Close monitoring of prevalence and the degree of
incidental detection of AAAs in the population is mandated.
If prevalence rates fall even further, general screening in
men may prove futile, and alternative strategies with tar-
geted screening of risk groups with higher prevalence, pri-
marily smokers, should be evaluated. Furthermore, research
on threshold values for ultrasound surveillance, the effect
on quality of life of screening, and targeted screening of
smoking women are indicated.CONFLICT OF INTEREST
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